{"schema_version":"secwatch.filing_event.v1","accession":"0002023658-25-000006","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.814879+00:00","generated_at":"2026-05-24T04:24:22.104868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bicara Therapeutics reports Q4 net loss $21M, cash $489.7M; pivotal Phase 2/3 trial dosing started","bullets":["Net loss $21.0M in Q4 2024, $68.0M full year; vs $12.4M and $52.0M in 2023.","Cash and equivalents $489.7M as of Dec 31, 2024, up from $230.4M; funds operations into first half 2029.","First patients dosed in February 2025 in FORTIFI-HN01, pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC.","Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting.","Three abstracts on ficerafusp alfa accepted for AACR 2025, including monotherapy in cSCC and preclinical lung cancer data."],"urls":{"canonical":"https://secwatch.observer/filing/0002023658-25-000006","json":"https://secwatch.observer/filing/0002023658-25-000006.json","markdown":"https://secwatch.observer/filing/0002023658-25-000006.md","text":"https://secwatch.observer/filing/0002023658-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000006/0002023658-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000006/bcax-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:24:22.104868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}